Abstract
Fc gamma receptors (FcγRs) are expressed on the surface of various immune cells, and the interactions between FcγRs and the Fc region of immunoglobulin G are involved in the activation of immune cells by antigen-bound antibodies. Fc-mediated immune-cell activations are related to both the efficacy and the safety of therapeutic monoclonal antibodies. It is indispensable to elucidate the Fc-mediated functions in the development of therapeutic monoclonal antibodies. Here, we describe a cell-based assay using FcγR-expressing reporter cell lines that can be used to evaluate the human FcγR-activation properties of therapeutic monoclonal antibodies by a rapid and simple procedure.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8(1):34–47. https://doi.org/10.1038/nri2206
Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10(5):317–327. https://doi.org/10.1038/nri2744
Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276(9):6591–6604. https://doi.org/10.1074/jbc.M009483200
Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ, Dahiyat BI (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 103(11):4005–4010. https://doi.org/10.1073/pnas.0508123103
Strohl WR (2009) Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 20(6):685–691. https://doi.org/10.1016/j.copbio.2009.10.011
Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M (2006) Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin Cancer Res 12(9):2879–2887. https://doi.org/10.1158/1078-0432.CCR-05-2619
Thomann M, Schlothauer T, Dashivets T, Malik S, Avenal C, Bulau P, Ruger P, Reusch D (2015) In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. PLoS One 10(8):e0134949. https://doi.org/10.1371/journal.pone.0134949
Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, Lissenberg-Thunnissen SN, Visser R, Brouwer M, Mok JY, Matlung H, van den Berg TK, van Esch WJE, Kuijpers TW, Wouters D, Rispens T, Wuhrer M, Vidarsson G (2017) Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities. Front Immunol 8:877. https://doi.org/10.3389/fimmu.2017.00877
Pichler WJ (2006) Adverse side-effects to biological agents. Allergy 61(8):912–920. https://doi.org/10.1111/j.1398-9995.2006.01058.x
Okuyama A, Nagasawa H, Suzuki K, Kameda H, Kondo H, Amano K, Takeuchi T (2011) Fcgamma receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 70(2):299–304. https://doi.org/10.1136/ard.2010.136283
Jonsson F, Mancardi DA, Zhao W, Kita Y, Iannascoli B, Khun H, van Rooijen N, Shimizu T, Schwartz LB, Daeron M, Bruhns P (2012) Human FcgammaRIIA induces anaphylactic and allergic reactions. Blood 119(11):2533–2544. https://doi.org/10.1182/blood-2011-07-367334
Rosales C (2017) Fcgamma receptor heterogeneity in leukocyte functional responses. Front Immunol 8:280. https://doi.org/10.3389/fimmu.2017.00280
Parekh BS, Berger E, Sibley S, Cahya S, Xiao L, LaCerte MA, Vaillancourt P, Wooden S, Gately D (2012) Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. MAbs 4(3):310–318. https://doi.org/10.4161/mabs.19873
Tada M, Ishii-Watabe A, Suzuki T, Kawasaki N (2014) Development of a cell-based assay measuring the activation of FcgammaRIIa for the characterization of therapeutic monoclonal antibodies. PLoS One 9(4):e95787. https://doi.org/10.1371/journal.pone.0095787
Takakura M, Tada M, Ishii-Watabe A (2017) Development of cell-based assay for predictively evaluating the FcgammaR-mediated human immune cell activation by therapeutic monoclonal antibodies. Biochem Biophys Res Commun 485(1):189–194. https://doi.org/10.1016/j.bbrc.2017.02.050
Findlay L, Eastwood D, Stebbings R, Sharp G, Mistry Y, Ball C, Hood J, Thorpe R, Poole S (2010) Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J Immunol Methods 352(1–2):1–12. https://doi.org/10.1016/j.jim.2009.10.013
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Aoyama, M., Tada, M., Ishii-Watabe, A. (2019). A Cell-Based Reporter Assay Measuring the Activation of Fc Gamma Receptors Induced by Therapeutic Monoclonal Antibodies. In: Steinitz, M. (eds) Human Monoclonal Antibodies. Methods in Molecular Biology, vol 1904. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8958-4_21
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8958-4_21
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8957-7
Online ISBN: 978-1-4939-8958-4
eBook Packages: Springer Protocols